729 related articles for article (PubMed ID: 26444287)
1. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2013 Jun; 31(25):2762-71. PubMed ID: 23588088
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2012 May; 30(22):3320-8. PubMed ID: 22386745
[TBL] [Abstract][Full Text] [Related]
9. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
11. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
15. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
16. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
20. [Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].
Qiu YP; Zhao K; Li X; Shi LW; Guo WD; Qi XR; Sui BY; Zhou RM
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1074-1078. PubMed ID: 28057111
[No Abstract] [Full Text] [Related]
[Next] [New Search]
